New cancer vaccine delivers striking results after five years

Date:

Share this article:

Del denne artikel:

Researchers say a personalized cancer vaccine is showing benefits that remain visible five years after treatment.

Cancer treatment is increasingly moving away from a one-size-fits-all approach. As medical science advances, researchers are focusing on therapies tailored to each individual patient, aiming to improve outcomes while reducing the risk of the disease returning.

New findings presented at the American Society of Clinical Oncology (ASCO) Annual Meeting suggest that a personalized mRNA vaccine could become an important tool in the fight against melanoma.

Researchers reported encouraging long-term results when the experimental vaccine was used alongside the immunotherapy drug Keytruda, reports Medical News Today.

Built for each patient

Unlike traditional treatments, the vaccine is created using genetic information taken from a patient's own tumor. Scientists analyze the cancer's unique mutations and design a vaccine intended to help the immune system identify and destroy remaining cancer cells.

Also read: These foods may help keep your brain sharp as you age

The study involved 157 patients with high-risk melanoma who had previously undergone surgery. Participants received either standard treatment with Keytruda or a combination of Keytruda and the personalized vaccine.

Results stand out

After five years of follow-up, researchers found a significant difference between the two groups. Patients receiving the combination therapy experienced a 59% lower risk of the cancer spreading to distant organs compared with those receiving Keytruda alone.

The data also showed higher overall survival rates among patients who received the personalized vaccine. Researchers believe the findings indicate that the immune response generated by the treatment may remain active for years after administration.

What's next?

Despite the promising results, experts caution that larger studies are still needed before the treatment can become part of routine clinical care. A phase 3 trial is already underway to confirm the findings in a broader patient population.

Also read: A child’s birth month may affect their risk of getting the flu

The manufacturing process also remains a challenge, as every vaccine must be custom-made from an individual patient's tumor sample. Even so, researchers see the latest results as a strong indication that personalized cancer vaccines may play a significant role in the future of oncology.

Sources: Medical News Today

Also read: Dermatologists: Your position in the shower may affect your skin health

This article is made and published by Mie Hermansen, who may have used AI in the preparation.

Other articles

Researchers discover how long-term money problems affect the brain

A British research project that followed participants for more than 70 years suggests that ongoing financial hardship may...

New study casts doubt on fish oil’s blood pressure benefits

New research suggests fish oil may not lower blood pressure as much as many people believe.

Common blood pressure drug linked to higher kidney risk

A new study suggests a widely prescribed blood pressure medication may be linked to a higher risk of kidney problems in people with type 2 diabetes.

How chefs make mashed potatoes creamier without adding more butter

Many people believe that adding more butter is the best way to make mashed potatoes creamy. However, chefs say the real secret is a simple cooking technique.

Researchers discover how long-term money problems affect the brain

A British research project that followed participants for more than 70 years suggests that ongoing financial hardship may...

New study casts doubt on fish oil’s blood pressure benefits

New research suggests fish oil may not lower blood pressure as much as many people believe.

Common blood pressure drug linked to higher kidney risk

A new study suggests a widely prescribed blood pressure medication may be linked to a higher risk of kidney problems in people with type 2 diabetes.